Logo image of ERYP

ERYTECH PHARMA - SPON ADR (ERYP) Stock Fundamental Analysis

NASDAQ:ERYP - Nasdaq - US29604W1080 - ADR - Currency: USD

0.78  0 (0%)

Fundamental Rating

2

ERYP gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. ERYP may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, ERYP is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ERYP had negative earnings in the past year.
In the past year ERYP has reported a negative cash flow from operations.
In the past 5 years ERYP always reported negative net income.
ERYP had a negative operating cash flow in each of the past 5 years.
ERYP Yearly Net Income VS EBIT VS OCF VS FCFERYP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -20M -40M -60M

1.2 Ratios

ERYP has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ERYP Yearly ROA, ROE, ROICERYP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -50 -100 -150 -200 -250

1.3 Margins

ERYP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ERYP Yearly Profit, Operating, Gross MarginsERYP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 -500 -1K -1.5K

More info and screens

3

2. Health

2.1 Basic Checks

ERYP does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ERYP has about the same amount of shares outstanding.
Compared to 1 year ago, ERYP has an improved debt to assets ratio.
ERYP Yearly Shares OutstandingERYP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M
ERYP Yearly Total Debt VS Total AssetsERYP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

2.2 Solvency

ERYP has an Altman-Z score of -2.54. This is a bad value and indicates that ERYP is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.54, ERYP is in line with its industry, outperforming 45.57% of the companies in the same industry.
A Debt/Equity ratio of 0.44 indicates that ERYP is not too dependend on debt financing.
ERYP's Debt to Equity ratio of 0.44 is on the low side compared to the rest of the industry. ERYP is outperformed by 71.50% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Altman-Z -2.54
ROIC/WACCN/A
WACC4.93%
ERYP Yearly LT Debt VS Equity VS FCFERYP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M 150M

2.3 Liquidity

ERYP has a Current Ratio of 3.65. This indicates that ERYP is financially healthy and has no problem in meeting its short term obligations.
ERYP has a Current ratio of 3.65. This is in the lower half of the industry: ERYP underperforms 61.67% of its industry peers.
ERYP has a Quick Ratio of 3.65. This indicates that ERYP is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ERYP (3.65) is worse than 60.71% of its industry peers.
Industry RankSector Rank
Current Ratio 3.65
Quick Ratio 3.65
ERYP Yearly Current Assets VS Current LiabilitesERYP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

ERYP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 99.68%, which is quite impressive.
The Revenue has grown by 59.04% in the past year. This is a very strong growth!
Measured over the past years, ERYP shows a quite strong growth in Revenue. The Revenue has been growing by 14.60% on average per year.
EPS 1Y (TTM)99.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%102.44%
Revenue 1Y (TTM)59.04%
Revenue growth 3Y7.96%
Revenue growth 5Y14.6%
Sales Q2Q%198.12%

3.2 Future

The Earnings Per Share is expected to grow by 26.28% on average over the next years. This is a very strong growth
ERYP is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -44.77% yearly.
EPS Next Y22.35%
EPS Next 2Y26.28%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year16.44%
Revenue Next 2Y16.85%
Revenue Next 3Y-56.11%
Revenue Next 5Y-44.77%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ERYP Yearly Revenue VS EstimatesERYP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M 20M
ERYP Yearly EPS VS EstimatesERYP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -1 -2 -3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ERYP. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ERYP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ERYP Price Earnings VS Forward Price EarningsERYP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ERYP Per share dataERYP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as ERYP's earnings are expected to grow with 26.28% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.28%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ERYP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ERYTECH PHARMA - SPON ADR

NASDAQ:ERYP (6/28/2023, 8:00:02 PM)

0.78

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-09 2023-05-09/amc
Earnings (Next)09-11 2023-09-11/amc
Inst Owners0.04%
Inst Owner Change-91.11%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap26.61M
Analysts42.22
Price Target3.94 (405.13%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)307.94%
Min Revenue beat(2)-81.61%
Max Revenue beat(2)697.48%
Revenue beat(4)1
Avg Revenue beat(4)118.61%
Min Revenue beat(4)-81.61%
Max Revenue beat(4)697.48%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)6.54%
EPS NQ rev (1m)0%
EPS NQ rev (3m)9.09%
EPS NY rev (1m)0%
EPS NY rev (3m)9.09%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.19
P/FCF N/A
P/OCF N/A
P/B 1.04
P/tB 1.04
EV/EBITDA N/A
EPS(TTM)-0.55
EYN/A
EPS(NY)-1.03
Fwd EYN/A
FCF(TTM)-1.02
FCFYN/A
OCF(TTM)-1.01
OCFYN/A
SpS0.24
BVpS0.75
TBVpS0.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.17
Health
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.84%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.65
Quick Ratio 3.65
Altman-Z -2.54
F-Score4
WACC4.93%
ROIC/WACCN/A
Cap/Depr(3y)10.07%
Cap/Depr(5y)458.36%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%102.44%
EPS Next Y22.35%
EPS Next 2Y26.28%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)59.04%
Revenue growth 3Y7.96%
Revenue growth 5Y14.6%
Sales Q2Q%198.12%
Revenue Next Year16.44%
Revenue Next 2Y16.85%
Revenue Next 3Y-56.11%
Revenue Next 5Y-44.77%
EBIT growth 1Y51.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.52%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y44.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.05%
OCF growth 3YN/A
OCF growth 5YN/A